Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 (Gastric Cancer, (2021), 24, 6, (1330-1340), 10.1007/s10120-021-01200-w)

Eric Van Cutsem*, Mayur Amonkar, Charles S. Fuchs, Maria Alsina, Mustafa Özgüroğlu, Yung Jue Bang, Hyun Cheol Chung, Kei Muro, Eray Goekkurt, Al B. Benson, Weijing Sun, Zev A. Wainberg, Josephine M. Norquist, Xinqun Chen, Chie Schin Shih, Kohei Shitara

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original publication of the article, the following sentences should be added before last under the “Declarations” heading.

Original languageEnglish (US)
Pages (from-to)1341
Number of pages1
JournalGastric Cancer
Volume24
Issue number6
DOIs
StatePublished - Nov 2021

ASJC Scopus subject areas

  • Gastroenterology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 (Gastric Cancer, (2021), 24, 6, (1330-1340), 10.1007/s10120-021-01200-w)'. Together they form a unique fingerprint.

Cite this